You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Looking Glass

    SBC: Intific, Inc.            Topic: 004

    Looking Glass is an immersive, story-driven game experience that enables computer science education for students K-12. It presents learning in a game-based series of challenging levels that permit a high degree of player choice in tailoring educational pr

    SBIR Phase II 2014 Department of DefenseDefense Advanced Research Projects Agency
  2. Novel Extensible Design Approaches for Advanced Aircraft Composite Structural Architectures (MSC P4168)

    SBC: MATERIALS SCIENCES LLC            Topic: ST13A006

    Among the factors that inhibit the use of composite materials in both general aviation aircraft and DoD platforms are the relatively high cost of engineering and certification. Unless manufacturers control risk when introducing new or advanced materials and processes for aircraft, the potential benefits will be lost to the industry. For small commercial applications the problem is compounded by ...

    STTR Phase II 2014 Department of DefenseDefense Advanced Research Projects Agency
  3. Biofuel Production from Grease Trap Waste

    SBC: Environmental Fuel Research, LLC            Topic: F

    Environmental Fuel Research, LLC, proposes to commercialize a grease trap waste to biofuel process based on process research from Drexel University. Grease trap waste is dirty and low-value material produced by the food service industry that is high in lipids that can be converted to biodiesel. The quantity of grease trap waste in the United States could produce one-half billion gallons of biodies ...

    SBIR Phase I 2014 Environmental Protection Agency
  4. Local Lymph Node Assay with IL-18 Endpoints

    SBC: MB RESEARCH LABORATORIES, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The current industry standard for predicting contact dermal sensitization is the murine Local Lymph Node Assay (LLNA). A significant limitation of the LLNA is the frequency of false positives, as well as the occurrenceof false negatives. This limitation occurs as a result of the LLNA inability to always correctly distinguish between substances that are strongly ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Ubiquitin pathway inhibitors for treatment of asthma

    SBC: Progenra, Inc            Topic: NIAID

    DESCRIPTION (provided by applicant): Asthma is a chronic disease with considerable morbidity and no cures. Symptomatic treatment is efficacious but produces significant adverse effects. Thus, improved, targeted therapies for asthma are needed. Asthma develops when T cells (CD4+) differentiate to effector T cells, which secrete cytokines that assist in the recruitment and proliferation of various i ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Host-Targeted Mechanism of Action for Treatment of Seasonal and Pandemic Influenz

    SBC: EVRYS BIO LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): Despite improvements in vaccine design, manufacture, and distribution, influenza A infection remains a significant public health concern. The February 2013 CDC Interim Adjusted Estimates of Seasonal Influenza Vaccine Effectiveness reported overall vaccine effectiveness of 56% and 67% against influenza A and B infections, respectively, with much reduced effect ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. A New Generation of Botulinum Toxin Vaccines

    SBC: INVENTOX INC            Topic: NIAID

    DESCRIPTION (provided by applicant): Botulinum toxin is one of the six categories of pathogens that have been designated as Category A Select Agents by the Centers for Disease Control. The toxin, which is generally acknowledged to be the most potent biological poison known, enters the body and acts on peripheral cholinergic nerve endings to cause paralysis of transmission. In seriously poisoned pa ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. A Single Antiviral to Treat Multiple Opportunistic Infections

    SBC: EVRYS BIO LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): Transplant patients are quite susceptible to opportunistic viral infection resulting from immune suppression necessary for maintenance of their graft. In the case of renal transplant, 17,604 patients in 2011, a new graft means being taken off dialysis, improving quality of life and saving U.S. healthcare nearly 1 B annually. Therefore it is essential that the ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Novel bispecific T cell engaging antibodies for treatment of Lyme disease

    SBC: ABZYME THERAPEUTICS LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): Lyme disease (LD) is the most commonly reported tick-borne illness in the United States. According to the recent Center for Disease Control and Prevention report, approximately 300,000 Lyme cases are diagnosed each year. If left untreated, the infection spreads to joints, the heart and the nervous system. In most cases, infections and associated symptoms are el ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. An antimicrobial-eluting bioresorbable bone filler for orthopaedic application

    SBC: CarMell Therapeutics Corporation            Topic: NIAMS

    DESCRIPTION (provided by applicant): The long-term goal of Carmell Therapeutics for this proposal is to develop a blood plasma-based biomaterial bone filler product that will elute antimicrobials to inhibit infection. Bacterial contamination is present perioperatively in 48-68% o all open wounds and 100% of severe open injuries. Per year in the U.S. ~ 123,000 open tibia fractures are contaminated, ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government